Navigation Links
New Anti-Clotting Drug Less Risky For Heart Attack Patients

A new study has found anti-clotting drug called bivalirudin (Angiomax) that beats the standard combination drug therapy for patients with acute coronary syndromes such as heart// attacks. This new blood thinner seems to be less risky for patients suffering from acute coronary syndromes.

The Results of the ‘Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial’ were published in November issue of the New England Journal of Medicine. The Medicines Company and Nycomed, which market Angiomax, funded the study. A team lead by Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education are conducting the research.

Dr. Stone said: "We use bivalirudin at Columbia in the vast majority of cases and have found out that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

The journal described a trial that involved around 14,000 patients with heart attack or other acute coronary syndromes. The patients were assigned to one of three drug regimens: a package treatment including heparin; a similar package including bivalirudin; or bivalirudin alone. The results showed that the patients treated with Angiomax, also known as bivalirudin, had similar rates of serious complications, such as death, heart attack and repeat artery clearing procedures as the other groups, but had significantly lower rates of serious bleeding.

Only 3 percent of those getting bivalirudin alone had major bleeding episodes comparing to that of 5.7 percent of those getting the heparin package, for patients, that makes all the difference, Stone said. Moreover, the researchers were able find that the incidences of artery blockages or major bleeding were also reduced by the usage of bivalirudin by about 14 percent compared to a drug package including heparin.

"The big difference was the reduction of major bleeding, almost 50 percent," Stone added. "Major bleeding has been associated with higher mortality, so it is important that bivalirudin, which reduced the risk of major bleeding up to 47 percent, could be reserved for patients with history of bleeding such as anemia.” – He added.

To conclude, the drug has been currently approved as a replacement for heparin in all nonemergency angioplasty procedures.
RI
'"/>




Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Herbal Remedy Risky for Cancer Patients
3. Risky Drugs To Be Avoided In The Elderly
4. HRT Not That Risky For Breast Cancer
5. Coffee In Pregnancy May Be Risky: Study
6. Distinct Brain Sections Are Activated While Making Risky Decisions
7. Americans Avoiding Risky Foods
8. Heavy Dosage Of Vitamin Supplements May Be Risky For Pregnant Women
9. Males Show More Risky Behaviour with Alcohol
10. Risky Behavior In Teenagers Leads To Depression
11. Insight Into The Risky Health Decisions On Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: